Of Mice And MAbs: UK’s Kymab Wins Case Against Regeneron
Patents That Disclose Insufficient Information Risk Invalidation
Executive Summary
Lawyers say a UK Supreme Court ruling invalidating Regeneron’s patent claims on transgenic mice could have a “profound effect” on the validity of patent claims in the life science sector.